Advertisement
Singapore markets open in 4 hours 24 minutes
  • Straits Times Index

    3,293.13
    +20.41 (+0.62%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • Dow

    38,460.92
    -42.77 (-0.11%)
     
  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     
  • Bitcoin USD

    63,828.88
    -2,438.84 (-3.68%)
     
  • CMC Crypto 200

    1,379.31
    -44.79 (-3.14%)
     
  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     
  • Gold

    2,328.80
    -13.30 (-0.57%)
     
  • Crude Oil

    82.76
    -0.60 (-0.72%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     
  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     
  • FTSE Bursa Malaysia

    1,571.48
    +9.84 (+0.63%)
     
  • Jakarta Composite Index

    7,174.53
    -7,110.81 (-49.78%)
     
  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

Analysts’ Ratings for FibroGen and Its Peers in April 2018

Analysts’ Ratings for FibroGen and Its Peers in April 2018

FibroGen (FGEN) is a biopharmaceutical company involved in the discovery and development of first-in-class therapeutics. The drug is in Phase 3 of development for the treatment of anemia in chronic kidney disease. The company has adopted a global approach to the development and commercialization of its product candidates.